MD4760B1 - Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D - Google Patents

Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D Download PDF

Info

Publication number
MD4760B1
MD4760B1 MDA20170014A MD20170014A MD4760B1 MD 4760 B1 MD4760 B1 MD 4760B1 MD A20170014 A MDA20170014 A MD A20170014A MD 20170014 A MD20170014 A MD 20170014A MD 4760 B1 MD4760 B1 MD 4760B1
Authority
MD
Moldova
Prior art keywords
hepatitis
virus
compositions
treatment
methods
Prior art date
Application number
MDA20170014A
Other languages
English (en)
Russian (ru)
Other versions
MD20170014A2 (ro
MD4760C8 (ro
Inventor
Эндрю Вайан
Original Assignee
Replicor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4760(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc. filed Critical Replicor Inc.
Publication of MD20170014A2 publication Critical patent/MD20170014A2/ro
Publication of MD4760B1 publication Critical patent/MD4760B1/ro
Publication of MD4760C8 publication Critical patent/MD4760C8/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Invenţia se referă la compoziţii şi metode de tratament al infecţiilor provocate de virusul hepatitei B sau de co-infecţia cu virusul hepatitei B şi virusul hepatitei D, care includ administrarea unui subiect ce are nevoie de un astfel de tratament al unui prim agent farmaceutic acceptabil, care conţine un complex chelat al cel puţin unui polimer al acidului nucleic tiofosfat şi al doilea agent farmaceutic acceptabil, care conţine cel puţin un analog nucleozidic/nucleotidic, care inhibă polimerazele HVB.Secvenţe: 20
MDA20170014A 2014-07-10 2015-07-07 Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D MD4760C8 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (3)

Publication Number Publication Date
MD20170014A2 MD20170014A2 (ro) 2017-07-31
MD4760B1 true MD4760B1 (ro) 2021-07-31
MD4760C8 MD4760C8 (ro) 2022-02-28

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20170014A MD4760C8 (ro) 2014-07-10 2015-07-07 Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D

Country Status (34)

Country Link
US (1) US9603865B2 (ro)
EP (1) EP3166615B1 (ro)
JP (2) JP2017521433A (ro)
KR (2) KR102734495B1 (ro)
CN (2) CN106659730A (ro)
AU (1) AU2015286199B2 (ro)
BR (1) BR112017000320B1 (ro)
CA (1) CA2954182C (ro)
CL (1) CL2017000008A1 (ro)
CU (1) CU20170001A7 (ro)
CY (1) CY1126361T1 (ro)
DK (1) DK3166615T3 (ro)
DO (1) DOP2017000002A (ro)
EA (1) EA036745B1 (ro)
EC (1) ECSP16097355A (ro)
ES (1) ES2963814T3 (ro)
FI (1) FI3166615T3 (ro)
HK (1) HK1231402A1 (ro)
HR (1) HRP20231400T1 (ro)
HU (1) HUE064449T2 (ro)
IL (1) IL249660B (ro)
LT (1) LT3166615T (ro)
MD (1) MD4760C8 (ro)
MX (1) MX381042B (ro)
MY (1) MY178087A (ro)
PH (1) PH12017500010B1 (ro)
PL (1) PL3166615T3 (ro)
PT (1) PT3166615T (ro)
RS (1) RS64833B1 (ro)
SG (1) SG11201700073PA (ro)
SI (1) SI3166615T1 (ro)
SM (1) SMT202300380T1 (ro)
TW (1) TWI766831B (ro)
WO (1) WO2016004525A1 (ro)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021005357A (es) * 2018-11-08 2021-06-30 Aligos Therapeutics Inc Polimeros oligonucleotidos que inhiben el transporte de antigeno s y metodos.
US11166976B2 (en) * 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
CN112010905B (zh) * 2020-05-07 2021-09-03 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦晶型及其应用
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN114057816B (zh) * 2020-07-30 2025-02-11 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
JP2005538186A (ja) 2002-09-13 2005-12-15 レプリコール インコーポレーティッド 非配列相補性の抗ウイルス性オリゴヌクレオチド
US9474793B2 (en) * 2005-02-22 2016-10-25 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant HIV-1 and hepatitis B virus
KR20150039873A (ko) 2010-08-20 2015-04-13 레플리코르 인코포레이티드 올리고뉴클레오타이드 킬레이트 복합체
EP3766975A1 (en) * 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
CA2873529C (en) 2012-05-18 2020-08-18 Replicor Inc. Oligonucleotide chelate complex-polypeptide compositions and methods
AR091065A1 (es) * 2012-05-18 2014-12-30 Replicor Inc Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral
EP2890403A4 (en) * 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS

Also Published As

Publication number Publication date
JP6922030B2 (ja) 2021-08-18
DK3166615T3 (da) 2023-11-13
MX381042B (es) 2025-03-12
KR102734495B1 (ko) 2024-11-25
CL2017000008A1 (es) 2017-06-09
TW201613617A (en) 2016-04-16
CA2954182A1 (en) 2016-01-14
US20160008393A1 (en) 2016-01-14
SG11201700073PA (en) 2017-02-27
EA036745B1 (ru) 2020-12-16
KR20170029577A (ko) 2017-03-15
BR112017000320A2 (pt) 2017-11-07
FI3166615T3 (fi) 2023-11-06
DOP2017000002A (es) 2017-03-15
HK1231402A1 (zh) 2017-12-22
TWI766831B (zh) 2022-06-11
PT3166615T (pt) 2023-11-13
AU2015286199B2 (en) 2020-05-14
JP2020143065A (ja) 2020-09-10
SI3166615T1 (sl) 2023-12-29
EP3166615A4 (en) 2018-01-17
EP3166615A1 (en) 2017-05-17
EA201790160A1 (ru) 2017-06-30
AU2015286199A1 (en) 2017-02-23
US9603865B2 (en) 2017-03-28
HRP20231400T1 (hr) 2024-02-16
PL3166615T3 (pl) 2024-02-19
CA2954182C (en) 2023-08-15
BR112017000320B1 (pt) 2023-02-07
PH12017500010A1 (en) 2017-05-15
ECSP16097355A (es) 2017-03-31
SMT202300380T1 (it) 2024-01-10
NZ727583A (en) 2024-08-30
PH12017500010B1 (en) 2022-07-29
MD20170014A2 (ro) 2017-07-31
CY1126361T1 (el) 2026-02-25
MY178087A (en) 2020-10-02
KR20230070330A (ko) 2023-05-22
HUE064449T2 (hu) 2024-03-28
EP3166615B1 (en) 2023-08-09
CN113750112A (zh) 2021-12-07
RS64833B1 (sr) 2023-12-29
JP2017521433A (ja) 2017-08-03
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
ES2963814T3 (es) 2024-04-02
MD4760C8 (ro) 2022-02-28
WO2016004525A1 (en) 2016-01-14
LT3166615T (lt) 2024-01-25
CN106659730A (zh) 2017-05-10
IL249660A0 (en) 2017-02-28
MX2017000053A (es) 2017-05-01

Similar Documents

Publication Publication Date Title
JOP20200092A1 (ar) تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EA201790160A1 (ru) Способы лечения инфекций, вызываемых вирусами гепатита b и гепатита d
EA201890494A1 (ru) Способы лечения вирусных инфекций arenaviridae и coronaviridae
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
BR112017013028A2 (pt) nucleosídeos, nucleotídeos e análogos dos mesmos substituídos
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201692535A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
LT3265102T (lt) Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201592075A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201592184A1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017501943A1 (en) Influenza virus neutralizing peptidomimetic compounds
EA202191771A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AR101126A1 (es) Composiciones para el tratamiento de infecciones por virus de hepatitis b y hepatitis d
TH1601005264A (ro)
EA202092602A3 (ru) Β-d-2'-дезокси-2'-α-фтор-2'-β-c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний

Legal Events

Date Code Title Description
FG4A Patent for invention issued
TK4A Erratum in official gazette in regard to patent for invention

Free format text: RECTIFICATION IN INID 30

KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)